The American Society of Hematology’s (ASH) annual meeting is a well-established indicator of the innovations that are coming down the pipeline for hematologic diseases. CBPartners’ Cell and Gene Therapy Center of Excellence explored eight promising presentations from the CAR T event.
Julia Pikus is an Associate Principal at CBPartners specialising in USA / EU5 value, pricing and access work, and with a focus on leveraging in-person research to enhance product or portfolio strategies across markets.
Connect with Julia Pikus
August 22, 2019 | Blog
In 2017, the first therapy designed to genetically modify patients’ own T-cells to attack cancer was FDA-approved, but are CAR T-cell therapies close to meeting the remaining needs of patients? CBPartners' Cell and Gene Therapy Center of Excellence investigates the current challenges and limitations of this therapy.